
Please try another search
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Dipal Doshi | 48 | 2017 | CEO & Director |
Mary T. Thistle | 64 | 2021 | Industry Leader & Independent Director |
Peter S. Kim | 65 | 2020 | Director |
Kush M. Parmar | 44 | 2016 | Independent Chairman of the Board |
Gina Chapman | 57 | 2023 | Independent Director |
Bernhardt G. Zeiher | 61 | 2023 | Independent Director |
Mahalakshmi Radhakrishnan | 55 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review